PTC Therapeutics
Rare Disease Therapeutics · Cell & Gene Therapy

PTC Therapeutics revenue, results and funding

PTC Therapeutics filed revenue of $1.7B for 2025.

Data updated Nov 18, 2026 · Back to the company report
$1.7BRevenue, 2025
$682.6MNet income, 2025

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_DEBTLANG_CR_S_M_ACQUISITIONS
2025$1.7B$682.6M$2.9B$36.9M$14M$8.9M$74.5M$455.2M$866.9M$984.6M––
2024$806.8M−$363.3M$1.7B$17.6M$176k$6.5M$74.6M$534.5M−$302.6M$779.7M$285.4M–
2023$937.8M−$626.6M$1.9B$14.2M−$69.5M$28.4M$101.6M$666.6M−$439.5M$594M$284.2M–
2022$698.8M−$559M$1.7B$4.9M−$28.5M$32M$110.3M$651.5M−$447.4M$279.8M$571.7M–
2021$538.6M−$523.9M$1.9B$7.7M$5.6M$28.2M$103.5M$540.7M−$374.4M$189.7M$281.9M–
2020$380.8M−$438.2M$2.2B$26.4M$35.2M$17.8M$70.3M$477.6M−$431.8M$208.8M$309.1M–
2019$307M−$251.6M$1.6B$2.1M$11.7M$13.8M$42.1M$257.5M−$241.2M$288M$293.9M$0
2018$264.7M−$128.1M$1.1B$1.6M−$29k$7.1M$33.3M$172M−$115.7M$169.5M$141.3M$48.9M
2017$194.4M−$79M$391.7M$1.1M$1.3M$3.1M$30.6M$117.5M−$64.3M$111.8M$145M$0
2016$82.7M−$142.1M$269.3M$943k$569k$1.8M$35M$117.6M−$132.1M$58.3M$98.2M$0
2015$36.8M−$170.4M$365.3M$111k$485k$2.7M$34M$121.8M−$167.1M$58M$91.8M–
2014$25.2M−$93.8M$333.2M$0−$4.7M$4.7M$19.3M$79.8M−$99.4M$49.7M––
2013$34.7M−$51.6M$151.9M$2k–$846k$8.4M$54.9M−$45.4M$15.4M––
2012$33.9M−$26.2M$13.1M$2k–$189k$2.3M$46.1M−$26.8M$2.7M$439k–
2011$105.4M$30.9M–$2.1k−$2.3M$165k$2.8M$58.7M$30.6M$28.4M––
Sources: SEC

How to cite

PTC Therapeutics, Financials. Alion, Nov 18, 2026. https://alion.io/company/ptcbio/financials

.json · .md · CC BY-SA 4.0